V
VRAX
vs
S&P 500
S&P 500
Over the past 12 months, VRAX has underperformed S&P 500, delivering a return of -86% compared to the S&P 500's +14% growth.
Stocks Performance
VRAX vs S&P 500
Performance Gap
VRAX vs S&P 500
Performance By Year
VRAX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Virax Biolabs Group Ltd
Glance View
Virax Biolabs Group Ltd is a GB-based company operating in Health Care Providers & Services industry. Virax Biolabs Group Limited is a biotechnology company. The firm is primarily engaged in the sales, distribution and marketing of diagnostics test kits and med-tech and personal protective equipment (PPE) products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The company is developing a T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral threats. Its product portfolio includes: ViraxClear, ViraxCare, and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Its products include antigen tests, polymerase chain reaction (PCR) rapid tests, and neutralizing antibody tests. ViraxCare develops and distributes advanced medical devices, technology, and PPE globally. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus.
